BLZ 100

Drug Profile

BLZ 100

Alternative Names: BLZ-100; Chlorotoxin conjugated to indocyanine green dye - Blaze Bioscience; CyTP-007

Latest Information Update: 07 Jun 2016

Price : $50

At a glance

  • Originator Blaze Bioscience
  • Class Biological toxins; Drug conjugates; Imaging agents; Indoles; Peptides
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glioma; Skin cancer; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 30 May 2016 Blaze Bioscience withdraws a phase I clinical trial in Soft tissue sarcoma in USA prior to enrolment (IV) (NCT02464332)
  • 01 Mar 2016 Blaze Bioscience completes a phase I trial in Glioma (Diagnosis) in USA and Australia (IV) (NCT02234297)
  • 09 Nov 2015 Interim adverse events data from a phase I trial in Glioma released by Blaze Bioscience
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top